TW321649B
(en)
*
|
1994-11-12 |
1997-12-01 |
Zeneca Ltd |
|
GB9424233D0
(en)
*
|
1994-11-30 |
1995-01-18 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508538D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508537D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9508535D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivative
|
GB9508565D0
(en)
*
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quiazoline derivative
|
WO1996033977A1
(en)
*
|
1995-04-27 |
1996-10-31 |
Zeneca Limited |
Quinazoline derivatives
|
GB9624482D0
(en)
|
1995-12-18 |
1997-01-15 |
Zeneca Phaema S A |
Chemical compounds
|
CA2242425C
(en)
|
1996-02-13 |
2006-07-18 |
Zeneca Limited |
Quinazoline derivatives as vegf inhibitors
|
GB9603097D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
GB9603095D0
(en)
*
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
IL125954A
(en)
|
1996-03-05 |
2003-06-24 |
Zeneca Ltd |
Quinazoline derivatives, processes for their preparation, pharmaceutical compositions containing them and use thereof in the manufacture of medicaments having an antiangiogenic and/or vascular permeability reducing effect
|
PT892789E
(en)
|
1996-04-12 |
2002-07-31 |
Warner Lambert Co |
IRREVERSIVE INHIBITORS OF TYROSINE KINASES
|
GB9607729D0
(en)
*
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9707800D0
(en)
|
1996-05-06 |
1997-06-04 |
Zeneca Ltd |
Chemical compounds
|
US6391874B1
(en)
|
1996-07-13 |
2002-05-21 |
Smithkline Beecham Corporation |
Fused heterocyclic compounds as protein tyrosine kinase inhibitors
|
JP2002505660A
(en)
|
1996-09-10 |
2002-02-19 |
ファルマシア・アンド・アップジョン・カンパニー |
8-Hydroxy-7-substituted quinolines as antiviral agents
|
AU733551B2
(en)
*
|
1996-09-25 |
2001-05-17 |
Astrazeneca Ab |
Qinoline derivatives inhibiting the effect of growth factors such as VEGF
|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
US7863444B2
(en)
|
1997-03-19 |
2011-01-04 |
Abbott Laboratories |
4-aminopyrrolopyrimidines as kinase inhibitors
|
EP1007042A4
(en)
*
|
1997-06-13 |
2001-07-04 |
Sugen Inc |
Novel heteroaryl compounds for the modulation of protein tyrosine enzyme related cellular signal transduction
|
WO1999010349A1
(en)
|
1997-08-22 |
1999-03-04 |
Zeneca Limited |
Oxindolylquinazoline derivatives as angiogenesis inhibitors
|
RS49779B
(en)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
GB9800575D0
(en)
*
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
US6706721B1
(en)
|
1998-04-29 |
2004-03-16 |
Osi Pharmaceuticals, Inc. |
N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
|
HUP0103386A3
(en)
*
|
1998-08-21 |
2002-07-29 |
Parker Hughes Inst St Paul |
Use of quinazoline derivatives for producing pharmaceutical compositions having jak 3-inhibitor effect
|
US6184226B1
(en)
|
1998-08-28 |
2001-02-06 |
Scios Inc. |
Quinazoline derivatives as inhibitors of P-38 α
|
US6713474B2
(en)
|
1998-09-18 |
2004-03-30 |
Abbott Gmbh & Co. Kg |
Pyrrolopyrimidines as therapeutic agents
|
BR9914326A
(en)
*
|
1998-10-08 |
2001-06-26 |
Astrazeneca Ab |
Use of a compound, compound, process for its preparation, pharmaceutical composition, and method to produce an anti-angiogenic and / or reduced vascular permeability effect in warm-blooded animals in need of such treatment
|
GB9822450D0
(en)
*
|
1998-10-14 |
1998-12-09 |
Smithkline Beecham Plc |
Medicaments
|
US8124630B2
(en)
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
CA2359244C
(en)
|
1999-01-13 |
2013-10-08 |
Bayer Corporation |
.omega.-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
WO2000043383A1
(en)
*
|
1999-01-20 |
2000-07-27 |
Smithkline Beecham P.L.C. |
Piperidinylquinolines as protein tyrosine kinase inhibitors
|
IL144745A0
(en)
|
1999-02-10 |
2002-06-30 |
Astrazeneca Ab |
Quinazoline derivatives as angiogenesis inhibitors
|
GB9904103D0
(en)
|
1999-02-24 |
1999-04-14 |
Zeneca Ltd |
Quinoline derivatives
|
GB9910580D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9910579D0
(en)
|
1999-05-08 |
1999-07-07 |
Zeneca Ltd |
Chemical compounds
|
GB9914486D0
(en)
|
1999-06-21 |
1999-08-18 |
Smithkline Beecham Plc |
Medicaments
|
TWI262914B
(en)
*
|
1999-07-02 |
2006-10-01 |
Agouron Pharma |
Compounds and pharmaceutical compositions for inhibiting protein kinases
|
MXPA01012887A
(en)
*
|
1999-07-07 |
2002-07-30 |
Astrazeneca Uk Ltd |
Quinazoline derivatives.
|
ES2295035T3
(en)
|
1999-07-09 |
2008-04-16 |
Glaxo Group Limited |
ANILINOQUINAZOLINAS AS INHIBITORS OF PROTEIN TIROSINA QUINASA.
|
US6933299B1
(en)
|
1999-07-09 |
2005-08-23 |
Smithkline Beecham Corporation |
Anilinoquinazolines as protein tyrosine kinase inhibitors
|
GB9917406D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
GB9917408D0
(en)
|
1999-07-23 |
1999-09-22 |
Smithkline Beecham Plc |
Compounds
|
SK3812002A3
(en)
|
1999-09-17 |
2003-09-11 |
Abbott Gmbh & Co Kg |
Pyrazolopyrimidines as therapeutic agents
|
US7071199B1
(en)
|
1999-09-17 |
2006-07-04 |
Abbott Gmbh & Cco. Kg |
Kinase inhibitors as therapeutic agents
|
BR0015203A
(en)
|
1999-11-05 |
2002-07-16 |
Astrazeneca Ab |
Quinazoline derivative, process for the preparation of a quinazoline derivative, pharmaceutical composition, use of a compound, and, process for the production of an anti-angiogenic and / or reducing effect on vascular permeability in a warm-blooded animal
|
UA74803C2
(en)
|
1999-11-11 |
2006-02-15 |
Осі Фармасьютікалз, Інк. |
A stable polymorph of n-(3-ethynylphenyl)-6,7-bis(2-methoxyetoxy)-4-quinazolinamine hydrochloride, a method for producing thereof (variants) and pharmaceutical use
|
US7087613B2
(en)
|
1999-11-11 |
2006-08-08 |
Osi Pharmaceuticals, Inc. |
Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
|
US7498335B2
(en)
|
2000-03-06 |
2009-03-03 |
Astrazeneca Ab |
Method of producing an antiangiogenic or vascular permeability reducing effect
|
US20030152572A1
(en)
*
|
2000-04-06 |
2003-08-14 |
Yoshimi Homma |
Diagnostic and therapeutic agents for rheumatoid arthritis
|
UA73993C2
(en)
|
2000-06-06 |
2005-10-17 |
Астразенека Аб |
Quinazoline derivatives for the treatment of tumours and a pharmaceutical composition
|
EP1296973B1
(en)
|
2000-06-24 |
2008-11-05 |
AstraZeneca AB |
Guanidine derivatives of quinazoline for use in the treatment of autoimmune diseases
|
DE60133897D1
(en)
|
2000-06-28 |
2008-06-19 |
Astrazeneca Ab |
SUBSTITUTED CHINAZOLIN DERIVATIVES AND THEIR USE AS AURORA-2-KINASE INHIBITORS
|
EP1305308B1
(en)
|
2000-07-26 |
2006-12-20 |
Smithkline Beecham Plc |
Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity
|
BR0113056A
(en)
|
2000-08-09 |
2003-07-08 |
Astrazeneca Ab |
Compound, process for preparation thereof, pharmaceutical composition, and method for producing an antiangiogenic and / or vascular permeability reducing effect in a warm-blooded animal, and use of a compound
|
KR20080027400A
(en)
|
2000-08-21 |
2008-03-26 |
아스트라제네카 아베 |
Quinazoline derivatives
|
US6756383B2
(en)
|
2000-09-01 |
2004-06-29 |
Chiron Corporation |
Heterocyclic derivatives of quinolinone benimidazoles
|
EP1317442B1
(en)
|
2000-09-11 |
2005-11-16 |
Chiron Corporation |
Quinolinone derivatives as tyrosine kinase inhibitors
|
AU2001293817A1
(en)
|
2000-09-20 |
2002-04-02 |
Merck Patent Gmbh |
4-amino-quinazolines
|
AU2001292138A1
(en)
|
2000-10-13 |
2002-04-22 |
Astrazeneca Ab |
Quinazoline derivatives with anti-tumour activity
|
EP1506962B1
(en)
|
2000-10-20 |
2008-07-02 |
Eisai R&D Management Co., Ltd. |
Nitrogen-containing aromatic heterocycles
|
US20040063733A1
(en)
*
|
2000-10-25 |
2004-04-01 |
Lambert Christine Marie Paul |
Quinazoline derivatives
|
DE60144284D1
(en)
|
2000-11-01 |
2011-05-05 |
Millennium Pharm Inc |
NITROGENIC HETEROCYCLIC COMPOUNDS AND METHOD FOR THE PRODUCTION THEREOF
|
WO2002036570A1
(en)
|
2000-11-02 |
2002-05-10 |
Astrazeneca Ab |
4-substituted quinolines as antitumor agents
|
JP2004514718A
(en)
|
2000-11-02 |
2004-05-20 |
アストラゼネカ アクチボラグ |
Substituted quinolines as anticancer agents
|
GB0101577D0
(en)
|
2001-01-22 |
2001-03-07 |
Smithkline Beecham Plc |
Compounds
|
DE60218138T2
(en)
*
|
2001-03-23 |
2007-09-20 |
Bayer Pharmaceuticals Corp., West Haven |
RHO-KINASE INHIBITORS
|
MXPA03008658A
(en)
*
|
2001-03-23 |
2005-04-11 |
Bayer Ag |
Rho-kinase inhibitors.
|
KR20040007497A
(en)
|
2001-04-16 |
2004-01-24 |
에자이 가부시키가이샤 |
Novel 1H-Indazole Compound
|
EP1381599B1
(en)
|
2001-04-19 |
2008-09-24 |
Astrazeneca AB |
Quinazoline derivatives
|
GB0112834D0
(en)
|
2001-05-25 |
2001-07-18 |
Smithkline Beecham Plc |
Medicaments
|
US7829566B2
(en)
|
2001-09-17 |
2010-11-09 |
Werner Mederski |
4-amino-quinazolines
|
KR100810468B1
(en)
*
|
2001-10-10 |
2008-03-07 |
씨제이제일제당 (주) |
1H-indole derivatives as a highly selective cyclooxygenase-2 inhibitor
|
RU2004116911A
(en)
*
|
2001-11-03 |
2005-11-10 |
Астразенека Аб (Se) |
Quinazoline derivatives as anti-tumor agents
|
GB0126433D0
(en)
*
|
2001-11-03 |
2002-01-02 |
Astrazeneca Ab |
Compounds
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
CN100491372C
(en)
|
2001-12-24 |
2009-05-27 |
阿斯特拉曾尼卡有限公司 |
Substituted quinazoline derivatives as inhibitors of aurora kinases
|
DE60320933D1
(en)
|
2002-01-10 |
2008-06-26 |
Bayer Healthcare Ag |
RHO-KINASE INHIBITORS
|
EP1470122B1
(en)
|
2002-01-23 |
2007-12-19 |
Bayer Pharmaceuticals Corporation |
Rho-kinase inhibitors
|
CA2473510A1
(en)
|
2002-01-23 |
2003-07-31 |
Bayer Pharmaceuticals Corporation |
Pyrimidine derivatives as rho-kinase inhibitors
|
AU2003239302A1
(en)
|
2002-01-29 |
2003-09-02 |
Glaxo Group Limited |
Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
|
WO2003064421A1
(en)
|
2002-01-29 |
2003-08-07 |
Glaxo Group Limited |
Aminopiperidine derivatives
|
PL371486A1
(en)
*
|
2002-02-01 |
2005-06-13 |
Astrazeneca Ab |
Quinazoline compounds
|
MXPA04007832A
(en)
|
2002-02-11 |
2005-09-08 |
Bayer Pharmaceuticals Corp |
Aryl ureas with angiogenesis inhibiting activity.
|
TW200302722A
(en)
*
|
2002-02-13 |
2003-08-16 |
Astrazeneca Ab |
Therapeutic agents
|
US7645878B2
(en)
|
2002-03-22 |
2010-01-12 |
Bayer Healthcare Llc |
Process for preparing quinazoline Rho-kinase inhibitors and intermediates thereof
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
ATE429230T1
(en)
|
2002-07-09 |
2009-05-15 |
Astrazeneca Ab |
CHINAZOLINE DERIVATIVES AND THEIR USE IN CANCER TREATMENT
|
GB0215823D0
(en)
|
2002-07-09 |
2002-08-14 |
Astrazeneca Ab |
Quinazoline derivatives
|
JP4703183B2
(en)
|
2002-07-15 |
2011-06-15 |
シンフォニー エボルーション, インク. |
Receptor kinase modulator and method of use thereof
|
US7585866B2
(en)
|
2002-07-31 |
2009-09-08 |
Critical Outcome Technologies, Inc. |
Protein tyrosine kinase inhibitors
|
US7825132B2
(en)
|
2002-08-23 |
2010-11-02 |
Novartis Vaccines And Diagnostics, Inc. |
Inhibition of FGFR3 and treatment of multiple myeloma
|
CA2496164C
(en)
|
2002-08-23 |
2010-11-09 |
Chiron Corporation |
Benzimidazole quinolinones and uses thereof
|
WO2004033446A1
(en)
|
2002-10-09 |
2004-04-22 |
Danter Wayne R |
Protein tyrosine kinase inhibitors
|
EP1581217A4
(en)
*
|
2002-11-01 |
2007-07-11 |
Merck & Co Inc |
Carbonylamino-benzimidazole derivatives as androgen receptor modulators
|
GB0225579D0
(en)
|
2002-11-02 |
2002-12-11 |
Astrazeneca Ab |
Chemical compounds
|
EP1562955B1
(en)
*
|
2002-11-04 |
2008-02-27 |
Astrazeneca AB |
Quinazoline derivatives as src tyrosine kinase inhibitors
|
CN100354278C
(en)
*
|
2002-11-04 |
2007-12-12 |
阿斯利康(瑞典)有限公司 |
Quinazoline derivatives as SRC tyrosine kinase inhibitors
|
KR20110108404A
(en)
|
2002-11-13 |
2011-10-05 |
노바티스 백신즈 앤드 다이아그노스틱스 인코포레이티드 |
Methods of treating cancer and related methods
|
DE10260730A1
(en)
*
|
2002-12-23 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Novel substituted nitrogen-containing heterobicyclene, their preparation and their use as pharmaceuticals
|
US7429597B2
(en)
|
2002-12-23 |
2008-09-30 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
Substituted nitrogen-containing heterobicycles, the preparation thereof and their use as pharmaceutical compositions
|
WO2004058781A1
(en)
|
2002-12-24 |
2004-07-15 |
Astrazeneca Ab |
Phosphonooxy quinazoline derivatives and their pharmaceutical use
|
GB0307333D0
(en)
*
|
2003-03-29 |
2003-05-07 |
Astrazeneca Ab |
Therapeutic agent
|
GB0309009D0
(en)
*
|
2003-04-22 |
2003-05-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
DE602004007382T2
(en)
|
2003-05-20 |
2008-04-17 |
Bayer Pharmaceuticals Corp., West Haven |
DIARYL UREAS FOR PDGFR MEDIATED DISEASES
|
GB0317665D0
(en)
|
2003-07-29 |
2003-09-03 |
Astrazeneca Ab |
Qinazoline derivatives
|
GB0318422D0
(en)
*
|
2003-08-06 |
2003-09-10 |
Astrazeneca Ab |
Chemical compounds
|
UA84167C2
(en)
|
2003-09-16 |
2008-09-25 |
Астразенека Аб |
Quinazoline derivatives as tyrosine kinase inhibitors, process for the preparation thereof (variants), pharmaceutical composition based thereon
|
GB0322409D0
(en)
|
2003-09-25 |
2003-10-29 |
Astrazeneca Ab |
Quinazoline derivatives
|
PL2210607T3
(en)
|
2003-09-26 |
2012-01-31 |
Exelixis Inc |
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
|
CN100450998C
(en)
|
2003-11-11 |
2009-01-14 |
卫材R&D管理有限公司 |
Urea derivative and process for producing the same
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
NZ547009A
(en)
|
2003-12-23 |
2009-09-25 |
Pfizer |
Novel quinoline derivatives
|
GB0330042D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions them
|
GB0330043D0
(en)
|
2003-12-24 |
2004-01-28 |
Pharmacia Italia Spa |
Pyrrolo [2,3-b] pyridine derivatives active as kinase inhibitors process for their preparation and pharmaceutical compositions comprising them
|
GB0330002D0
(en)
|
2003-12-24 |
2004-01-28 |
Astrazeneca Ab |
Quinazoline derivatives
|
AU2005207946A1
(en)
|
2004-01-23 |
2005-08-11 |
Amgen Inc. |
Quinoline quinazoline pyridine and pyrimidine counds and their use in the treatment of inflammation angiogenesis and cancer
|
BRPI0507373A
(en)
|
2004-01-23 |
2007-07-10 |
Amgen Inc |
compounds and method of use
|
EP1713781B1
(en)
|
2004-02-03 |
2008-11-05 |
AstraZeneca AB |
Quinazoline derivatives
|
JP5019884B2
(en)
|
2004-02-20 |
2012-09-05 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
Regulation of inflammatory and metastatic processes
|
EA011237B1
(en)
|
2004-05-06 |
2009-02-27 |
УОРНЕР-ЛАМБЕРТ КОМПАНИ Эл-Эл-Си |
4-phenylamino-quinazolin-6-yl-amides
|
US20070232607A1
(en)
*
|
2004-06-04 |
2007-10-04 |
Bradbury Robert H |
Quinazoline Derivatives as Erbb Receptor Tyrosine kinases
|
EP1781293A1
(en)
|
2004-06-04 |
2007-05-09 |
Amphora Discovery Corporation |
Quinoline- and isoquinoline-based compounds exhibiting atp-utilizing enzyme inhibitory activity, and compositions, and uses thereof
|
WO2006030826A1
(en)
|
2004-09-17 |
2006-03-23 |
Eisai R & D Management Co., Ltd. |
Medicinal composition
|
CA2581516C
(en)
|
2004-10-12 |
2013-06-11 |
Astrazeneca Ab |
Quinazoline derivatives
|
EP1827434B1
(en)
|
2004-11-30 |
2014-01-15 |
Amgen Inc. |
Quinolines and quinazoline analogs and their use as medicaments for treating cancer
|
WO2006064196A1
(en)
|
2004-12-14 |
2006-06-22 |
Astrazeneca Ab |
Pyrazolopyrimidine compounds as antitumor agents
|
ES2319462T3
(en)
|
2005-03-28 |
2009-05-07 |
Bristol-Myers Squibb Company |
COMPETITIVE INHIBITORS OF ATP CINASAS.
|
JO2787B1
(en)
|
2005-04-27 |
2014-03-15 |
امجين إنك, |
Substituted Amid derivatives & methods of use
|
GB0508715D0
(en)
*
|
2005-04-29 |
2005-06-08 |
Astrazeneca Ab |
Chemical compounds
|
PT1885187E
(en)
|
2005-05-13 |
2013-12-16 |
Novartis Ag |
Methods for treating drug resistant cancer
|
US8222413B2
(en)
|
2005-05-17 |
2012-07-17 |
Novartis Ag |
Methods for synthesizing heterocyclic compounds
|
CA2609353C
(en)
|
2005-05-23 |
2015-04-28 |
Novartis Ag |
Crystalline and other forms of 4-amino-5-fluoro-3-[6-(4-methylpiperazin-1-yl)-1h-benzimidazol-2-yl]-1h-quinolin-2-one lactic acid salts
|
CN101263125A
(en)
*
|
2005-07-15 |
2008-09-10 |
先灵公司 |
Quinazoline derivatives useful in cancer treatment
|
WO2007015578A1
(en)
|
2005-08-02 |
2007-02-08 |
Eisai R & D Management Co., Ltd. |
Method for assay on the effect of vascularization inhibitor
|
US7820683B2
(en)
|
2005-09-20 |
2010-10-26 |
Astrazeneca Ab |
4-(1H-indazol-5-yl-amino)-quinazoline compounds as erbB receptor tyrosine kinase inhibitors for the treatment of cancer
|
AU2007215247B2
(en)
|
2006-02-10 |
2012-12-13 |
Transtech Pharma, Llc |
Benzazole derivatives, compositions, and methods of use as Aurora kinase inhibitors
|
UY30183A1
(en)
|
2006-03-02 |
2007-10-31 |
Astrazeneca Ab |
QUINOLINE DERIVATIVES
|
CN101443009A
(en)
|
2006-05-18 |
2009-05-27 |
卫材R&D管理有限公司 |
Antitumor agent for thyroid cancer
|
CN101511793B
(en)
|
2006-08-28 |
2011-08-03 |
卫材R&D管理有限公司 |
Antitumor agent for undifferentiated gastric cancer
|
EP1921070A1
(en)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclic heterocycles, medicaments comprising them, their use and process for their preparation
|
JP5319306B2
(en)
|
2007-01-29 |
2013-10-16 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
Composition for treatment of undifferentiated gastric cancer
|
AU2008212999A1
(en)
|
2007-02-06 |
2008-08-14 |
Boehringer Ingelheim International Gmbh |
Bicyclic heterocycles, drugs containing said compounds, use thereof, and method for production thereof
|
ATE547415T1
(en)
*
|
2007-09-21 |
2012-03-15 |
Janssen Pharmaceutica Nv |
INHIBITORS OF THE INTERACTION BETWEEN MDM2 AND P53
|
UA101168C2
(en)
|
2007-10-29 |
2013-03-11 |
Натко Фарма Лимитед |
Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
|
WO2009058267A2
(en)
|
2007-10-29 |
2009-05-07 |
Amgen Inc. |
Benzomorpholine derivatives and methods of use
|
CN101848895B
(en)
|
2007-11-09 |
2013-10-23 |
卫材R&D管理有限公司 |
Combination of anti-angiogenic substance and anti-tumor platinum complex
|
WO2009079797A1
(en)
|
2007-12-26 |
2009-07-02 |
Critical Outcome Technologies, Inc. |
Compounds and method for treatment of cancer
|
KR20100111291A
(en)
|
2008-02-07 |
2010-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production
|
WO2009138781A1
(en)
|
2008-05-13 |
2009-11-19 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- { [1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
|
CA2730890C
(en)
|
2008-07-17 |
2018-05-15 |
Critical Outcome Technologies Inc. |
Thiosemicarbazone inhibitor compounds and cancer treatment methods
|
EP2313397B1
(en)
|
2008-08-08 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
|
PL2387563T5
(en)
|
2009-01-16 |
2023-03-13 |
Exelixis, Inc. |
Malate salt of n- (4- { [ 6, 7-bis (methyloxy) quinolin-4-yl]oxy}phenyl-n' - (4 -fluorophenyl) cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
|
UA108618C2
(en)
|
2009-08-07 |
2015-05-25 |
|
APPLICATION OF C-MET-MODULATORS IN COMBINATION WITH THEMOSOLOMID AND / OR RADIATION THERAPY FOR CANCER TREATMENT
|
MX2012002099A
(en)
|
2009-09-03 |
2012-04-11 |
Bristol Myers Squibb Co |
Quinazolines as potassium ion channel inhibitors.
|
EP3235818A3
(en)
|
2010-04-01 |
2018-03-14 |
Critical Outcome Technologies, Inc. |
Compounds for the treatment of hiv
|
US9012458B2
(en)
|
2010-06-25 |
2015-04-21 |
Eisai R&D Management Co., Ltd. |
Antitumor agent using compounds having kinase inhibitory effect in combination
|
CA2803387C
(en)
*
|
2010-07-29 |
2017-12-05 |
Bayard R. Huck |
Cyclic amine azaheterocyclic carboxamides
|
CA2828713C
(en)
|
2011-03-04 |
2022-08-16 |
Newgen Therapeutics, Inc. |
Alkyne substituted quinazoline compounds and methods of use
|
CA2828946C
(en)
|
2011-04-18 |
2016-06-21 |
Eisai R&D Management Co., Ltd. |
Therapeutic agent for tumor
|
EP3444363B1
(en)
|
2011-06-03 |
2020-11-25 |
Eisai R&D Management Co., Ltd. |
Biomarkers for prediciting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
|
CN102942561A
(en)
*
|
2012-11-06 |
2013-02-27 |
深圳海王药业有限公司 |
4-amino quinazoline heterocyclic compound and purpose of 4-amino quinazoline heterocyclic compound
|
CA2889866A1
(en)
|
2012-12-21 |
2014-06-26 |
Eisai R&D Management Co., Ltd. |
Amorphous form of quinoline derivative, and method for producing same
|
EP2956138B1
(en)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutic compounds and uses thereof
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
CN107915751A
(en)
|
2013-02-20 |
2018-04-17 |
卡拉制药公司 |
Therapeutic compound and its purposes
|
CA2901267C
(en)
|
2013-04-04 |
2021-01-19 |
Janssen Pharmaceutica Nv |
Novel n-(2,3-dihydro-1h-pyrrolo[2,3-b]pyridin-5-yl)-4-quinazolinamine and n-(2,3-dihydro-1h-indol-5-yl)-4-quinazolinamine derivatives as perk inhibitors
|
NZ714049A
(en)
|
2013-05-14 |
2020-05-29 |
Eisai R&D Man Co Ltd |
Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
|
TW201534597A
(en)
*
|
2013-06-20 |
2015-09-16 |
Ab Science |
Benzimidazole derivatives as selective proteine kinase inhibitors
|
DK3311845T3
(en)
|
2013-09-16 |
2020-04-06 |
Astrazeneca Ab |
THERAPEUTIC POLYMER NANOPARTICLES AND PROCEDURES FOR PREPARING AND USING THEREOF
|
EP3062618B1
(en)
|
2013-11-01 |
2020-02-05 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
MD4779B1
(en)
*
|
2014-04-04 |
2021-12-31 |
Pfizer Inc. |
Bicyclic-fused heteroaryl or aryl compounds and their use as IRAK4 inhibitors
|
CN106660964B
(en)
|
2014-08-28 |
2021-09-03 |
卫材R&D管理有限公司 |
High-purity quinoline derivative and process for producing the same
|
US20180028662A1
(en)
|
2015-02-25 |
2018-02-01 |
Eisai R&D Management Co., Ltd. |
Method for Suppressing Bitterness of Quinoline Derivative
|
KR20170122809A
(en)
|
2015-03-04 |
2017-11-06 |
머크 샤프 앤드 돔 코포레이션 |
A combination of a PD-1 antagonist and a VEGFR / FGFR / RET tyrosine kinase inhibitor to treat cancer
|
CN104725364B
(en)
*
|
2015-03-12 |
2017-09-15 |
江苏省中国科学院植物研究所 |
The amine derivative of 6,7 dimethoxyquinazoline 4, its preparation method and medical usage
|
RU2729936C2
(en)
|
2015-06-16 |
2020-08-13 |
Эйсай Ар Энд Ди Менеджмент Ко., Лтд. |
Anticancer agent
|
US20190112317A1
(en)
|
2015-10-05 |
2019-04-18 |
The Trustees Of Columbia University In The City Of New York |
Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies
|
CN106045980B
(en)
*
|
2016-06-03 |
2017-11-03 |
江苏开放大学 |
A kind of quinazoline derivant and preparation method thereof
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US10253036B2
(en)
|
2016-09-08 |
2019-04-09 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CN109688818A
(en)
|
2016-09-08 |
2019-04-26 |
卡拉制药公司 |
Crystal form of therapeutic compounds and application thereof
|
WO2018197642A1
(en)
|
2017-04-27 |
2018-11-01 |
Astrazeneca Ab |
C5-anilinoquinazoline compounds and their use in treating cancer
|
EP3615526B1
(en)
*
|
2017-04-27 |
2021-08-04 |
Astrazeneca AB |
Phenoxyquinazoline compounds and their use in treating cancer
|
KR20240017986A
(en)
*
|
2017-09-26 |
2024-02-08 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
Compositions and methods for treating cancer
|
FR3080620B1
(en)
*
|
2018-04-27 |
2021-11-12 |
Univ Paris Sud |
COMPOUNDS WITH TUBULIN POLYMERIZATION INHIBITOR ACTIVITY AND IMMUNOMODULATORY PROPERTIES
|